Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Oncologists who Treat RCC (US)

Council Members in this Study Group: 49

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Donald Fleming, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INCDonald Fleming

Division Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed...

Taral Patel, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel

Oncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer,...

Al Barqawi, Assistant Professor , University of Colorado Health Sciences Center - CCAl Barqawi

Assistant Professor
University of Colorado Health Sciences Center - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Al Barqawi, MD, FRCS, is Assistant Professor and Lecturer in the Division of Urology at University of Colorado Health Science Center. Dr. Barqawi also serves as Director of Research in the Section of Urologic Oncology. He has expertise in urologic oncology...

Eric Whitman, Medical Director, Office of Grants and Research, ATLANTIC HEALTH SYSTEM INCEric Whitman

Medical Director, Office of Grants and Research
ATLANTIC HEALTH SYSTEM INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Eric Whitman, MD, is the Medical Director of the Office of Grants and Research for Atlantic Health System in Morristown, New Jersey. He is a board certified General Surgeon with fellowship training in surgical oncology. He specializes in melanoma care,...

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Herceptin's broader horizons

January 30, 2010

Roche gets EU approval for Herceptin to treat HER2-positive advanced stomach cancer | www.pharmabiz.com

There has been between a 20-30% Her over expression detected on adeno ca of gastric mucosaThe fastest growing esophageal malignancy is GE junction adenoca, which acts and is treated very similar to adeno ca of stomachOther solid tumors are likely to also demonstrate a similar benefit

New Cancer Target: PARP

December 16, 2009

BiPar Sciences' BSI-201 phase-3 trial makes progress in metastatic triple-negative breast cancer | www.pharmabiz.com

Recent evidence suggest that PARP is a new enzyme related target for TNBCTNBC sorely needs more effective therapyBe certain, the PARP target is not TNBC specific

Gleevec move over for Tasigna

December 10, 2009

Novartis' Tasigna demonstrates greater efficacy over Glivec in chronic myeloid leukaemia | www.pharmabiz.com

Gleevec has revolutionized outcome/ therapy in CMLRecent phase III demonstrates better tolerance of Tasigna over GleevecCML outcome is reflected in MR and Tasigna seems to do it better

Roche's Avastin declined by European "bean counters" for brain tumor

November 23, 2009

European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer | www.pipelinereview.com

Avastin utilized successfully in US for primary brain tumors, including the very aggressive GBMHealth care, including cancer, will be all about rationingRoche and other pharma companys better get ready for a rough future

Omapro will fill a CML void

November 14, 2009

US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com

Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*
  • Other Freestanding Healthcare Facility

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Partner
  • Physician - Division Head
  • President
  • Owner
  • Medical Director